泰恩康(301263.SZ)控股子公司CKBA乳膏申报儿童白癜风临床试验获受理

Core Viewpoint - The company, Tianenkang (301263.SZ), announced that its subsidiary, Jiangsu Bochuangyuan Biopharmaceutical Technology Co., Ltd. (referred to as "Bochuangyuan"), has received a notice of acceptance from the National Medical Products Administration, allowing the submission of a clinical research application for CKBA cream combined with narrowband ultraviolet B (NB-UVB) for the treatment of non-segmental vitiligo in children aged 2 to 12 years [1] Group 1 - The acceptance notice pertains to a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study [1] - The study will evaluate the safety, tolerability, efficacy, and pharmacokinetic characteristics of CKBA cream in the specified age group [1]